Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 328

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 328
---
 investment. We have a very limited
operating history, are in the pre-clinical stage of development of our product candidate, have never generated revenues, have not paid
dividends, and are unlikely to pay dividends in the immediate or near future. The likelihood of our being able to achieve our goals and
run our business must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered
in connection with the establishment of early-stage biotechnology companies. An investment in our securities may result in the loss of
the entirety of such investment. Only stockholders and potential stockholders who are experienced in high-risk investments and who can
afford to lose their entire investment should consider an investment in our securities.

Certain
of our founding stockholders, plus our existing officers and directors, control a substantial interest in us and thus may influence certain
actions requiring stockholder vote.

Our
founding stockholders, which include five trusts for the benefit of the family of our founder Johnnie R. Williams, Sr., as well as MIRALOGX,
collectively own in excess of 70% of our issued and outstanding common stock. Brian McNulty acts as the trustee for such trusts. Our
officers and directors also own shares of our common stock. Therefore, these entities and individuals could influence the outcome of
matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions.

Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock.

Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur as a result
of our utilization of a universal shelf registration statement or otherwise could depress the market price of our common stock and impair
our ability to raise capital through the sale of additional equity securities. Notably, a large number of shares of our common stock
held by founding stockholders of our company have been registered for public resale and could be sold on the public market, depressing
our stock price. Moreover, we cannot in general predict the effect that future sales of our common stock or the market perception that
we are permitted to sell a significant number of our securities would have on the market price of our common stock.

40

The
requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract
and retain executive management and